Novel Bispecific Degrader BHV-1310 Eliminates Intravascular and Interstitial IgG within Multiple Organs and Anatomical Structures Including the Neuromuscular Junction

Real-World Treatment Outcomes in Patients with Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis Who Transitioned from Efgartigimod to Ravulizumab

Rapid Recovery in Atypical Guillain-Barre Syndrome with Afgartigimod Treatment